Curogen

Curogen is a clinical-stage biotechnology company based in South Korea that specializes in developing innovative peptide therapeutics for metabolic and age-related diseases. The company's core research focuses on mitochondrial-derived peptides (MDPs), which function as key regulators of cellular energy homeostasis and systemic metabolism. Its lead candidate, CRG-101, is a modified MDP analog designed to treat non-alcoholic steatohepatitis (NASH) and obesity by enhancing energy expenditure and reducing hepatic fat accumulation. Beyond metabolic disorders, Curogen is leveraging its platform to address unmet needs in sarcopenia and neurodegenerative conditions such as Alzheimer's disease. The company aims to advance the field of geroscience by restoring mitochondrial health and metabolic balance in aging populations.